Summit (Oxford) Limited
Records under this name other than the patents Summit (Oxford) Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 8 of 8 · Back to Summit (Oxford) Limited
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,318,487 | Solid tablet dosage form of ridinilazole Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,383,665 | Immunomodulatory compositions Term ended Term ended Jul 22, 2024 · From the USPTO record | Term ended | Term ended Jul 22, 2024 | From the USPTO record |
| US 9,278,091 | Compounds for the treatment of Clostridium difficile associated disease Lapsed on the fee record Ended Mar 8, 2024 · From the USPTO record | Lapsed on the fee record | Ended Mar 8, 2024 | From the USPTO record |
| US 8,557,859 | Immunomodulatory compositions Term ended Term ended Jan 21, 2024 · From the USPTO record | Term ended | Term ended Jan 21, 2024 | From the USPTO record |
| US 8,518,980 | Treatment of Duchenne muscular dystrophy Lapsed on the fee record Ended Aug 27, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2021 | From the USPTO record |
| US 8,501,713 | Drug combinations for the treatment of duchenne muscular dystrophy Lapsed on the fee record Ended Aug 6, 2021 · From the USPTO record | Lapsed on the fee record | Ended Aug 6, 2021 | From the USPTO record |
| US 9,492,433 | Pharmaceutical composition for the treatment of Duchenne muscular dystrophy Lapsed on the fee record Ended Nov 15, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2020 | From the USPTO record |
| US 8,138,351 | Treatment of duchenne muscular dystrophy Lapsed on the fee record Ended Mar 20, 2020 · From the USPTO record | Lapsed on the fee record | Ended Mar 20, 2020 | From the USPTO record |